Ms. Shelia Gail Mcferron, MA/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 515 Old Somerset Road, Mt.vernon, KY 40456 Phone: 606-308-3270 Fax: 606-256-3120 |
News Archive
U.S. workfare programs have been praised by some for cutting welfare rolls and improving the economic well-being of families. But little is known about how these policies affected participants' health and mortality.
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
In a new report out of Italy, health officials reported that almost 99 percent of people who have died from COVID-19 since February 2021 were not fully vaccinated. The report released by the National Health Institute (ISS) showed that the few fully vaccinated people who died of COVID-19 were also older than those who died without complete COVID-19 vaccine doses.
The group that advises the U.S. government on vaccination thinks some new vaccines may not be worth the cost. In 2009, the Advisory Committee on Immunization Practices, or ACIP, decided it's not cost effective to routinely vaccinate boys for human papillomavirus, though they do recommend the vaccine for girls.
A research team led by U of T Mississauga scientists has developed a new way to split up a dangerous pair of cancer proteins, a finding that could ultimately lead to chemotherapy that is more effective and has fewer side effects.
› Verified 6 days ago